Willingness to accept risk with medication in return for cure of symptoms among patients with Rome IV irritable bowel syndrome.
Journal Article (Journal Article)
BACKGROUND: Some drugs for irritable bowel syndrome (IBS) have serious side effects. AIMS: To examine the willingness of individuals with IBS to accept risks with medication in return for symptom cure. METHODS: We collected demographic, gastrointestinal symptoms, psychological health, quality of life and impact on work and daily activities data from 752 adults with Rome IV-defined IBS. We examined median willingness to accept death in return for cure with a hypothetical medication using a standard gamble, according to these variables. RESULTS: Participants would accept a median 2.0% (IQR 0.0%-9.0%) risk of death in return for a 98.0% (IQR 91.0%-100.0%) chance of permanent symptom cure. The median accepted risk of death was higher in men (5.0% vs 2.0%, P < 0.001), those with continuous abdominal pain (4.0% vs 1.0%, P < 0.001), more severe symptoms (P = 0.005 for trend), abnormal depression scores (P < 0.001 for trend), higher gastrointestinal symptom-specific anxiety (P < 0.001 for trend), and lower IBS-related quality of life (P < 0.001 for trend). Those willing to accept above median risk of death were more likely to be male (17.1% vs 9.1%, P < 0.001), take higher levels of risks in their daily life (P = 0.008 for trend), and report continuous abdominal pain (53.1% vs 39.4%, P < 0.001), and had higher depression (P = 0.004 for trend) and lower quality of life (P < 0.001 for trend) scores. CONCLUSION: Patients are willing to accept significant risks in return for cure of their IBS symptoms.
Full Text
Duke Authors
Cited Authors
- Goodoory, VC; Ng, CE; Black, CJ; Ford, AC
Published Date
- May 2022
Published In
Volume / Issue
- 55 / 10
Start / End Page
- 1311 - 1319
PubMed ID
- 35166374
Pubmed Central ID
- PMC9303338
Electronic International Standard Serial Number (EISSN)
- 1365-2036
Digital Object Identifier (DOI)
- 10.1111/apt.16816
Language
- eng
Conference Location
- England